NCT01257607已完成2 期
A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Corneal staining
研究概览
简要总结
The objective of this study is to compare the safety and efficacy of 1% MIM-D3 and 5% MIM-D3 to placebo for the treatment of the signs and symptoms of dry eye.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be at least 18 years of age
- •Provide written informed consent
- •Have a reported history of dry eye
- •Have a history of use or desire to use eye drops for dry eye
排除标准
- •Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months
- •Have any planned ocular and/or lid surgeries over the study period
- •Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1
- •Have an uncontrolled systemic disease
- •Be a woman who is pregnant, nursing or planning a pregnancy
- •Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study
- •Have a known allergy and/or sensitivity to the test article or its components
- •Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
- •Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1
- •Be unable or unwilling to follow instructions, including participation in all study assessments and visits
研究组 & 干预措施
Placebo Ophthalmic Solution
Placebo Comparator
干预措施: Placebo Ophthalmic Solution (Drug)
1% MIM-D3 Ophthalmic Solution
Experimental
干预措施: MIM-D3 Ophthalmic Solution (Drug)
5% MIM-D3 Ophthalmic Solution
Experimental
干预措施: MIM-D3 Ophthalmic Solution (Drug)
结局指标
主要结局
Corneal staining
时间窗: 28 days
Ocular surface damage
次要结局
- Conjunctival redness(42 days)
- Tear film break-up time(42 days)
- Tear osmolarity(42 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry EyeDry Eye SyndromesNCT01960010Mimetogen Pharmaceuticals USA, Inc.403
已完成
不适用
Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular DrynessDry EyeNCT03517748Horus Pharma80
已完成
3 期
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaPathological MyopiaNCT01217944Novartis Pharmaceuticals277
已完成
3 期
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μgAsthmaNCT02091986AstraZeneca882
Unknown
3 期
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne VulgarisAcne VulgarisNCT02491060Valeant Pharmaceuticals800